Literature DB >> 17702780

Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis.

Simon Cronin1, Matthew J Greenway, Jochen H M Prehn, Orla Hardiman.   

Abstract

BACKGROUND: The paraoxonases, PON1-3, play a major protective role both against environmental toxins and as part of the antioxidant defence system. Recently, non-synonymous coding single nucleotide polymorphisms (SNPs), known to lower serum PON activity, have been associated with sporadic ALS (SALS) in a Polish population. A separate trio based study described a detrimental allele at the PON3 intronic variant INS2+3651 (rs10487132). Association between PON gene cluster variants and SALS requires external validation in an independent dataset. AIMS: To examine the association of the promoter SNPs PON1(-162G>A) and PON1(-108T>C); the non-synonymous functional SNPs PON1(Q192R and L55M) and PON2(C311S and A148G); and the intronic marker PON3(INS2+3651A>G), with SALS in a genetically homogenous population.
METHODS: 221 Irish patients with SALS and 202 unrelated control subjects were genotyped using KASPar chemistries. Statistical analyses and haplotype estimations were conducted using Haploview and Unphased software. Multiple permutation testing, as implemented in Unphased, was applied to haplotype p values to correct for multiple hypotheses.
RESULTS: Two of the seven SNPs were associated with SALS in the Irish population: PON1(55M) (OR 1.52, p = 0.006) and PON3(INS2+3651 G) (OR 1.36, p = 0.03). Two locus haplotype analysis showed association only when both of these risk alleles were present (OR 1.7, p = 0.005), suggesting a potential effect modification. Low functioning promoter variants were observed to influence this effect when compared with wild-type.
CONCLUSIONS: These data provide additional evidence that genetic variation across the paroxanase loci may be common susceptibility factors for SALS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17702780      PMCID: PMC2117866          DOI: 10.1136/jnnp.2006.112581

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  23 in total

1.  Pedigree disequilibrium tests for multilocus haplotypes.

Authors:  Frank Dudbridge
Journal:  Genet Epidemiol       Date:  2003-09       Impact factor: 2.135

Review 2.  Occurrence of amyotrophic lateral sclerosis among Gulf War veterans.

Authors:  R D Horner; K G Kamins; J R Feussner; S C Grambow; J Hoff-Lindquist; Y Harati; H Mitsumoto; R Pascuzzi; P S Spencer; R Tim; D Howard; T C Smith; M A K Ryan; C J Coffman; E J Kasarskis
Journal:  Neurology       Date:  2003-09-23       Impact factor: 9.910

3.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

4.  Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids.

Authors:  S T Reddy; D J Wadleigh; V Grijalva; C Ng; S Hama; A Gangopadhyay; D M Shih; A J Lusis; M Navab; A M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-04       Impact factor: 8.311

5.  Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein.

Authors:  C J Ng; D J Wadleigh; A Gangopadhyay; S Hama; V R Grijalva; M Navab; A M Fogelman; S T Reddy
Journal:  J Biol Chem       Date:  2001-09-28       Impact factor: 5.157

6.  Risk factors for motor neuron disease: a case-control study based on patients from the Scottish Motor Neuron Disease Register.

Authors:  A M Chancellor; J M Slattery; H Fraser; C P Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

7.  Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes.

Authors:  S Adkins; K N Gan; M Mody; B N La Du
Journal:  Am J Hum Genet       Date:  1993-03       Impact factor: 11.025

8.  Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis.

Authors:  Elias Zintzaras; Georgios M Hadjigeorgiou
Journal:  J Hum Genet       Date:  2004-08-04       Impact factor: 3.172

9.  Paraoxonase protects against chlorpyrifos toxicity in mice.

Authors:  W F Li; C E Furlong; L G Costa
Journal:  Toxicol Lett       Date:  1995-04       Impact factor: 4.372

10.  Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction.

Authors:  N Martinelli; D Girelli; O Olivieri; C Stranieri; E Trabetti; F Pizzolo; S Friso; I Tenuti; S Cheng; M A Grow; P F Pignatti; R Corrocher
Journal:  Eur J Clin Invest       Date:  2004-01       Impact factor: 4.686

View more
  19 in total

1.  The paraoxonase disruption hypothesis in sporadic ALS steamrolled.

Authors:  Philipp G Sand
Journal:  Neurol Sci       Date:  2016-02-17       Impact factor: 3.307

Review 2.  ALS drug development: reflections from the past and a way forward.

Authors:  Swati Aggarwal; Merit Cudkowicz
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

3.  The role of environmental mercury, lead and pesticide exposure in development of amyotrophic lateral sclerosis.

Authors:  Frank O Johnson; William D Atchison
Journal:  Neurotoxicology       Date:  2009-07-24       Impact factor: 4.294

4.  Paraoxonase gene mutations in amyotrophic lateral sclerosis.

Authors:  Nicola Ticozzi; Ashley Lyn LeClerc; Pamela J Keagle; Jonathan D Glass; Anne-Marie Wills; Marka van Blitterswijk; Daryl A Bosco; Ildefonso Rodriguez-Leyva; Cinzia Gellera; Antonia Ratti; Franco Taroni; Diane McKenna-Yasek; Peter C Sapp; Vincenzo Silani; Clement E Furlong; Robert H Brown; John E Landers
Journal:  Ann Neurol       Date:  2010-07       Impact factor: 10.422

Review 5.  Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis.

Authors:  Emanuele D'Amico; Pam Factor-Litvak; Regina M Santella; Hiroshi Mitsumoto
Journal:  Free Radic Biol Med       Date:  2013-06-21       Impact factor: 7.376

Review 6.  Genetics of amyotrophic lateral sclerosis.

Authors:  Nailah Siddique; Teepu Siddique
Journal:  Phys Med Rehabil Clin N Am       Date:  2008-08       Impact factor: 1.784

7.  Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis: the GENEVA study. Rationale, study design and demographic characteristics.

Authors:  Silke Schmidt; Kelli D Allen; Valerie T Loiacono; Barbara Norman; Catherine L Stanwyck; Kristina M Nord; Christina D Williams; Edward J Kasarskis; Freya Kamel; Valerie McGuire; Lorene M Nelson; Eugene Z Oddone
Journal:  Neuroepidemiology       Date:  2008-04-18       Impact factor: 3.282

Review 8.  Recent advances in the genetics of amyotrophic lateral sclerosis.

Authors:  Paul N Valdmanis; Hussein Daoud; Patrick A Dion; Guy A Rouleau
Journal:  Curr Neurol Neurosci Rep       Date:  2009-05       Impact factor: 5.081

Review 9.  ALS and FTD: an epigenetic perspective.

Authors:  Veronique V Belzil; Rebecca B Katzman; Leonard Petrucelli
Journal:  Acta Neuropathol       Date:  2016-06-09       Impact factor: 17.088

10.  A common haplotype within the PON1 promoter region is associated with sporadic ALS.

Authors:  John E Landers; Lijia Shi; Ting-Jan Cho; Jonathan D Glass; Christopher E Shaw; P Nigel Leigh; Frank Diekstra; Meraida Polak; Ildefonso Rodriguez-Leyva; Stephan Niemann; Bryan J Traynor; Diane McKenna-Yasek; Peter C Sapp; Ammar Al-Chalabi; Anne-Marie A Wills; Robert H Brown
Journal:  Amyotroph Lateral Scler       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.